Congress created Inter Partes Review (IPR) to improve patent quality and expedite access to safe and affordable generic and biosimilar medicines. But there’s still work to do to tackle areas of congestion and eliminate roadblocks that drive up drug prices.

Let’s strengthen IPR to accelerate patient access and lower prescription drug prices

336,849 Patent applications in 2019

19 hours On average, how long did patent examiners review the extraordinarily technical features of each application?

TAKE A SECOND LOOK

PUT THE BRAKES ON LARGE PATENT PORTFOLIOS

SUCCESSFUL IPR CASE STUDY

ZYTIGA®

In 2018, the Patent Trial and Appeal Board (PTAB) invalidated claims of the patent on Zytiga®. The Federal Circuit affirmed the PTAB’s decision in 2019. Patients who were paying more than $5,600 for the brand-name drug now have an average of 81% discount savings due to generic medicine competition.

GIVE IPR THE GREEN LIGHT

It’s time for Congress to take action to enhance the Patent and Trademark Office’s IPR authority. Expediting access to lower-cost generics and biosimilar medicines will result in lower drug prices for U.S. patients.

Learn more at accessiblemeds.org

#DoesntAddUp

Source: Congressional Budget Office, Inter-Partes Review: A promising tool for addressing issues of patent durability, but challenges remain, February 2017

Source: Congressional Budget Office, Inter-Partes Review: A promising tool for addressing issues of patent durability, but challenges remain, February 2017